Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Atreca, Inc. (BCEL) stock declined over -0.90% intraday to trade at $2.21 a share on NASDAQ. The stock opened with a gain of 21.43% at $2.2 and touched an intraday high of $2.29, falling -0.90% against the last close of $2.23. The stock went to a low of $2.1 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $2.2 | $2.29 | $2.1 | $2.21 | 215,284 |
2022-07-05 | $1.82 | $2.27 | $1.72 | $2.23 | 610,000 |
2022-07-01 | $1.76 | $1.86 | $1.76 | $1.79 | 95,700 |
2022-06-30 | $1.83 | $1.86 | $1.76 | $1.79 | 111,900 |
2022-06-29 | $2.01 | $2.02 | $1.83 | $1.83 | 175,800 |
2022-06-28 | $1.99 | $2.1 | $1.972 | $2.03 | 124,800 |
2022-06-27 | $1.96 | $2.05 | $1.83 | $2.02 | 154,700 |
2022-06-24 | $1.91 | $2.18 | $1.9 | $1.96 | 3,346,500 |
2022-06-23 | $1.73 | $1.93 | $1.71 | $1.93 | 240,800 |
2022-06-22 | $1.74 | $1.9 | $1.64 | $1.7 | 433,300 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Atreca, Inc. (NASDAQ: BCEL) stock price is $2.21 as of the last check on Wednesday, July 6. During the trading session, BCEL stock reached the peak price of $2.29 while $2.1 was the lowest point it dropped to.
The NASDAQ listed BCEL is part of Biotechnology industry that operates in the broader Health Care sector. Atreca, Inc. , a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
Mr. John A. Orwin
Pres, CEO & Director
Mr. Herbert C. Cross
Chief Financial Officer
Dr. Tito A. Serafini Ph.D.
Founder, Chief Strategy Officer & Director
Dr. Yann Chong Tan
Chief Technologist
BCEL stock traded closed the last session at $2.21, which is $-0.02 or -0.90% lower than its previous close of $2.23. BCEL's current trading price is 46.36% lower than its 52-week high of $9.77 where as its distance from 52-week low of 1.51% is -77.38%.
Number of BCEL employees currently stands at -. BCEL operates from 835 Industrial Road, Suite 400, South San Francisco, CA 94070, United States.
Official Webiste of $BCEL is: https://www.atreca.com
BCEL could be contacted at BCEL operates from 835 Industrial Road, Suite 400, South San Francisco, CA 94070, United States, or at phone #650 595 2595 and can also be accessed through its website.
BCEL stock volume for the day was 215,709 shares while in the previous session number of BCEL shares traded was 215,284 . The average number of BCEL shares traded daily for last 3 months was 337.26 Thousands.
The percentage change in BCEL stock occurred in the recent session was -0.90% while the dollar amount for the price change in BCEL stock was $-0.02.
In the recent session, the day high for BCEL stock was $2.29 while the low for BCEL stock touched on the day was $2.1.
The market value of BCEL currently stands at 85.31 Million with its latest stock price at $2.21 and 37.98 Million of its shares outstanding.